Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorGylden Pharma Ltd
About this trial
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
Eligibility criteria
Qualifiers
Healthy volunteers aged 18 to 75 years on the day of inclusion
Participant signed informed consent
Residing in Philippines.
A participant can be included providing COVID-19 polymerase chain reaction (PCR) test is negative at screening.
Disqualifiers
Participant is pregnant, lactating, or of childbearing potential
Participation in the 6 months preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
Receipt of any vaccination against COVID-19 less than 6 months prior to participation in study.
Receipt of any vaccine in the three months preceding the first trial vaccination or planned receipt of any vaccine in the 6 months following last trial vaccination.
Trial design
Treatments tested in this trial
- PepGNP-COVID19 (One vaccination)
- Water for injection (One vaccination)
- PepGNP-COVID19 (Two vaccinations)
- Water for injection (Two vaccinations)
Treatment groups
110 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov